News

Updated dosing offers meaningful clinical benefit

Company says treatment shows strong efficacy and convenient dosing profile

Specialist group to review preclinical and clinical proposals ahead of funding decision

European Commission authorises therapy for children and adults with early‑onset disease

Phase 3 studies report meaningful reductions in exacerbations across broad patient groups

CHMP decision allows self‑administration from phase 5 for people with multiple myeloma

Laigo Bio has completed the second close of its seed financing round at €5.5m, bringing the total raised to €17m

Axplora has announced plans to build a 4,500sqm R&D and laboratory hub at its Farmabios site in Gropello Cairoli in Italy

DNA Script has signed distribution agreements with Gencell, Bio-Medical Science (BMS) and Biostream, expanding global access to its SYNTAX platform.

Ondine Biomedical has announced the North American phase 3 study has reached more than 93% enrolment, bringing the company closer to FDA submission.

Early trial shows more than 50% LRRK2 reduction and supports expansion into other neurodegenerative conditions

Lead Alzheimer’s candidate shows clear biological effects and antidepressant potential

Deal covers up to five candidates including SB36 as company expands global pipeline

Study to explore mechanism behind novel oral therapy for muscle‑sparing weight loss

Financing and global licensing deal to accelerate phase 2b development of AP306